In the News

LONDON – October 16, 2023 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients …

Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole Read More »

LONDON, June 08, 2023 — Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering …

Pulmocide Announces Expansion of Management Team Read More »

Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic …

Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole Read More »

Pulmocide Ltd. (“the Company”), a late-stage biopharmaceutical company focused on the development of a novel inhaled azole therapy for patients …

Pulmocide Receives Investment from the Cystic Fibrosis Foundation Read More »

Pulmocide raised $92 million in Series C funds in May 2021 to fund a registration program for opelconazole in patients …

Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA Read More »

– Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and …

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 Read More »

London, UK, 11 March 2021 – Pulmocide Ltd., which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, …

Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections Read More »

London, UK, 26 October 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives initially for targeted treatment of life-threatening …

Pulmocide Presents at US FDA Workshop on Inhaled Antifungal Drug Development Read More »

London, UK, 2 March 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung …

Pulmocide announces four presentations on PC945 at the 9th Advances Against Aspergillosis and Mucormycosis conference in Lugano, Switzerland, 27 February – 1 March, 2020 Read More »